Our Preclinical Services:
Translational studies
With Pelago Bioscience’s CETSA®-powered translational services, you can seamlessly extend your research from simplified systems to biologically relevant contexts. Our technology measures target engagement directly within cell lines, animal tissues, and human primary cells—providing a clear picture of how your compound performs in environments that better reflect real-world conditions. These insights help you make confident, evidence-based decisions, increasing the likelihood of clinical success and reducing the risks associated with trial failures.
Key Benefits
Streamlined Progression to Clinical Trials – Make informed, data-driven decisions that minimize costly trial failures and accelerate development timelines.
Physiologically Relevant Validation – Confirm target engagement across cell lines, animal tissues, and human-derived systems for reliable translational insights.
Reduced Development Risk—Validating efficacy in complex biological environments Strengthens confidence in your compound’s clinical potential.
In vivo target engagement
This data-driven approach offers a comprehensive view of drug distribution, bioavailability, and on-target interaction within living systems. The result is faster, more confident decision-making—helping you assess efficacy and safety before entering human trials.
Key Benefits
Accelerated Preclinical Decision-Making – Increase confidence in advancing compounds with proven efficacy and safety profiles before clinical trials.
Direct In Vivo Validation – Accurately measure target engagement within living organisms, providing meaningful data on drug behaviour.
Enhanced Drug Distribution Insights – Evaluate whether your compound reaches and engages its intended site of action across tissues and organs.
Biomarker discovery
Integrating CETSA into your biomarker discovery efforts can improve clinical success rates, optimize treatment strategies, and contribute to better patient survival outcomes.
Key Benefits
Clinically Relevant Validation – Ensure biomarkers are applicable by testing in patient-derived materials throughout development.
Unbiased Biomarker Discovery – Identify novel biomarkers linked to drug response through comprehensive proteome-wide profiling.
Enhanced Precision Medicine Support – Discover biomarkers that help predict patient response and guide personalized treatment strategies.